Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020092382 - CANCER SPECIFIC IMMUNOTHERAPEUTIC TARGETS GENERATED BY CHEMOTHERAPEUTIC DRUG TREATMENT

Publication Number WO/2020/092382
Publication Date 07.05.2020
International Application No. PCT/US2019/058582
International Filing Date 29.10.2019
IPC
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61K 39/39 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C12Q 1/68 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Applicants
  • HEALTH RESEARCH, INC. [US]/[US]
  • UNIVERSITY OF CONNECTICUT [US]/[US]
  • GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. [US]/[US]
Inventors
  • IONOV, Yurij
  • SRIVASTAVA, Pramod
  • MANDOIU, Ion
  • ZELIKOVSKY, Alex
Agents
  • WATT, Rachel, S.
  • LOPINSKI, John, D.
  • ROMAN, Paul, J.
  • KADLE, Ranjana
  • DIMAIO, John, T.m.
Priority Data
62/752,14929.10.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CANCER SPECIFIC IMMUNOTHERAPEUTIC TARGETS GENERATED BY CHEMOTHERAPEUTIC DRUG TREATMENT
(FR) CIBLES IMMUNOTHÉRAPEUTIQUES SPÉCIFIQUES DU CANCER GÉNÉRÉES PAR TRAITEMENT MÉDICAMENTEUX CHIMIOTHÉRAPEUTIQUE
Abstract
(EN)
Provided are methods for identifying antigens containing amino acid sequences for use in a cancer vaccine. The vaccines and methods of use for prophylaxis and/or therapy of cancer are included. The method involves: i) exposing cancer cells to a chemotherapeutic agent that damages DNA; ii) determining open reading frames encoded by mRNA transcribed from a gene in the cancer cells of i); iii) comparing the open reading frames of the mRNA of i) to open reading frames encoded by mRNA transcribed from the gene in the cancer cells that were not exposed to the chemotherapeutic agent, iv) determining a different open reading frame encoded by the mRNA of i) and an open reading frame of the mRNA of ii), wherein the different open reading frame encoded by the mRNA of i) encodes a contiguous amino acid sequence comprising the sequence of the antigen for use in the cancer vaccine.
(FR)
L'invention concerne des méthodes d'identification d'antigènes contenant des séquences d'acides aminés pour une utilisation dans un vaccin contre le cancer. Les vaccins et les méthodes d'utilisation pour la prophylaxie et/ou la thérapie du cancer sont inclus. La méthode consiste à : i) exposer des cellules cancéreuses à un agent chimiothérapeutique qui endommage l'ADN ; ii) déterminer des cadres de lecture ouverts codés par un ARNm transcrit à partir d'un gène dans les cellules cancéreuses de l'étape i) ; iii) comparer les cadres de lecture ouverts de l'ARNm de l'étape i) à des cadres de lecture ouverts codés par l'ARNm transcrit à partir du gène dans les cellules cancéreuses qui n'ont pas été exposées à l'agent chimiothérapeutique, iv) déterminer un cadre de lecture ouvert différent codé par l'ARNm de l'étape i) et un cadre de lecture ouvert de l'ARNm de l'étape ii), le cadre de lecture ouvert différent codé par l'ARNm de l'étape i) codant une séquence d'acides aminés adjacente comprenant la séquence de l'antigène destinée à être utilisée dans le vaccin contre le cancer.
Latest bibliographic data on file with the International Bureau